In conclusion, our study demonstrates that measurement of Gal-1 levels by ELISA is a novel method for improving PDA diagnosis, which could eventually lead to predicting prognosis of patients with unresectable tumors. This evidence concerns the gene LGALS1 and Patent ductus arteriosus.